anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

118,921-118,980 of 319,975

filter-aware
01
Slide 1
Page 1 of 3CPI Property Group (CPIPGR) · Carson Block
Shareholder letter Short seller 1 hit
02
This is an activist investor letter (Muddy Waters) demanding transparency on specific historical transactions.CPI Property Group (CPIPGR) · Carson Block
Shareholder letter Short seller Beat · ComplicationLoop · Cost Of Inaction1 hit
03
This slide functions as a list of investigative questions directed at management, likely from a short-seller report.CPI Property Group (CPIPGR) · Carson Block
Shareholder letter Short seller Beat · EvidenceLoop · Cost Of Inaction1 hit
07
The text argues that the rapid reversal of UACR effects upon drug cessation indicates a transient hemodynamic impact rather than structural renal improvement.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
08
The slide argues that the drug Atrasentan acts as a 'band-aid' by masking symptoms via surrogate endpoints without providing long-term structural benefit.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
09
The slide uses Kaplan-Meier survival curves to illustrate the convergence of outcomes between placebo and Atrasentan groups.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
10
The slide provides a critical analysis of a standard medical metric, highlighting its inaccuracies and limitations in clinical practice.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
11
The slide functions as a critique of clinical trial data integrity, specifically focusing on the inclusion of serum creatinine doubling and the use of inulin as a gold standard.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
12
The slide uses bar charts to show baseline vs treatment effects on GFR, ERBF, EFF, and ERVR, suggesting these metrics are influenced by blood dilution.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
13
The slide uses a table to highlight discrepancies in mortality reporting between the 'Enrichment' group and the 'Double-Blind' groups.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
14
Includes references to clinical trial data and expert commentary regarding cardiovascular and renal side effects of atrasentan.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
15
The text explicitly alleges data tampering regarding Acute Kidney Injury (AKI) reporting in the SONAR study.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
16
The slide highlights discrepancies in reported clinical trial data, specifically regarding ESKD progression and adverse event reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
17
The slide uses a table to highlight inconsistent reporting of Acute Kidney Injury (AKI) across different study groups and provides a narrative critique of cardiac failure reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
18
The slide uses Kaplan-Meier survival curves to illustrate the effects of Atrasentan on primary composite renal outcomes in different patient cohorts.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
19
The slide argues that the drug causes fluid retention and anemia, contradicting the trial's stated conclusions.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
20
The text argues that the omission of hematocrit data in the SONAR trial masks a hemodynamic effect that would undermine claims of renal improvement.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
21
The slide uses a callout box for trial results and follows with a critical analysis of anemia as a side effect.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
22
Includes extensive footnotes citing regulatory documents and investor call transcripts.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
23
Includes a table detailing orphan drug designation and marketing approval for Filspari (sparsentan).Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
24
This is a text-heavy research note page focusing on competitive critique and data skepticism.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
25
The slide critiques the visual representation of clinical trial data, specifically the 'time-distorting' nature of the x-axis in the provided graph.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
26
The slide highlights inconsistencies between SONAR study reports and FDA filings, suggesting data manipulation to favor the drug's safety profile.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
27
The slide uses a table of clinical trial results to illustrate a methodological critique of composite endpoints.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
28
The text focuses on statistical manipulation in clinical trial endpoints and discrepancies in patient count reporting between AFFINITY and ALIGN studies.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
29
The slide uses a 'villain critique' approach to undermine the credibility of the company's clinical trial reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
30
The slide uses a combination of text-based argument and visual data (charts) to expose potential manipulation of clinical trial reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
31
Includes critical commentary on the ALIGN trial and potential data obfuscation.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
32
Figure from SONAR trial report.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
33
Poster format including background, baseline/safety data, efficacy results, and conclusions.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
34
Includes detailed diagrams of disease pathophysiology and clinical trial design.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
35
The slide displays a forest plot comparing eGFR decline rates between atrasentan and placebo groups, segmented by pre-trial eGFR slope, UACR, and baseline eGFR.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
36
Data source identified as FDA SONAR data.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
01
Slide 1
Chinook Therapeutics Inc (KDNY)Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
02
This is a research note from Muddy Waters Research, acting as a short-seller report.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The MonsterLoop · The Reveal1 hit
03
This slide functions as a forensic accounting critique, highlighting specific instances of alleged financial misreporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The MonsterLoop · The Reveal1 hit
04
This is a text-heavy research note page focusing on accounting irregularities and investor behavior.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · The Reveal1 hit
05
The slide uses forensic accounting analysis to challenge the legitimacy of reported revenue and the operational substance of the SanReno joint venture.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · The Reveal1 hit
06
Includes annotations translating key fields to English.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Loop · The Reveal1 hit
07
The slide details specific accounting irregularities regarding warrant valuation and cost reimbursements, supported by extensive footnotes referencing SEC filings.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Loop · The Reveal1 hit
08
The slide argues that certain revenue should be reported as net rather than gross, citing specific 10-K filings.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Loop · The Reveal1 hit
09
The slide uses a table to adjust reported revenue and then provides a qualitative argument citing FASB standards to challenge the company's accounting method.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
10
The slide highlights a discrepancy in accounting treatment between two joint ventures to suggest financial manipulation.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
01
Slide 1
Standard legal boilerplate for investment research firm.Vivion Investments · Carson Block
Research note Short seller Beat · Hook1 hit
02
The slide sets up a 'before/after' or 'reality vs. representation' critique typical of short-seller research notes.Vivion Investments · Carson Block
Research note Short seller Beat · Expose Contradiction1 hit
03
Uses hyperbolic language ('gulags') and external citation (The Guardian) to frame the property negatively.Vivion Investments · Carson Block
Research note Short seller 1 hit
04
The slide uses a news headline as a hook to introduce a valuation discrepancy argument.Vivion Investments · Carson Block
Research note Short seller Beat · Thesis Headline1 hit
05
This is a text-heavy research note slide focusing on corporate governance and potential financial misconduct.Vivion Investments · Carson Block
Research note Short seller 1 hit
06
The slide highlights a discrepancy in valuation for the Crowne Plaza London Heathrow asset between two different sources (Vivion vs CBRE).Vivion Investments · Carson Block
Research note Short seller Beat · Appendix Data1 hit
07
Includes a specific highlight on Crowne Plaza London Heathrow in the footer.Vivion Investments · Carson Block
Research note Short seller 1 hit
01
Slide 1
Sunrun Inc. (RUN)Sunrun Inc. (RUN) · Muddy Waters Research
Activist deck Short seller Beat · Introduction1 hit
02
Sunrun Inc. (RUN)Sunrun Inc. (RUN) · Muddy Waters Research
Activist deck Short seller Beat · Introduction1 hit
03
The slide uses a dark, high-contrast aesthetic typical of activist short-seller reports.Sunrun Inc. (RUN) · Muddy Waters Research
Activist deck Short seller Beat · Introduction1 hit
04
The slide uses aggressive, informal language ('dumpster fire') characteristic of Muddy Waters activist reports.Sunrun Inc. (RUN) · Muddy Waters Research
Activist deck Short seller Beat · Introduction of the problem1 hit
05
The slide uses a provocative title to frame the financial data as poor performance.Sunrun Inc. (RUN) · Muddy Waters Research
Activist deck Short seller Beat · Introduction of the problem1 hit
06
The slide uses a waterfall bridge to deconstruct the 'Net Subscriber Value' metric.Sunrun Inc. (RUN) · Muddy Waters Research
Activist deck Short seller 1 hit
07
The table demonstrates high sensitivity to discount rates, with values dropping significantly as rates increase, highlighting the discrepancy between the model's 4-8% rates and the actual 16.5% cost of debt.Sunrun Inc. (RUN) · Muddy Waters Research
Activist deck Short seller 1 hit
08
Sunrun Inc. (RUN)Sunrun Inc. (RUN) · Muddy Waters Research
Activist deck Short seller 1 hit
09
The table includes specific exclusions/inclusions for Vivint Solar in early periods.Sunrun Inc. (RUN) · Muddy Waters Research
Activist deck Short seller 1 hit
10
The slide uses a rhetorical question to pivot the narrative toward the mechanics of fraud.Sunrun Inc. (RUN) · Muddy Waters Research
Activist deck Short seller 1 hit